Data / Form D filings / Renibus Therapeutics, Inc.
Renibus Therapeutics, Inc.: Form D filings
Renibus Therapeutics, Inc., a pharmaceuticals company in Southlake, TX, filed 14 Form D notices with the SEC between 2016 and 2025. The latest, on July 17, 2025, reports $110.9 million sold of a $110.9 million offering to 59 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 181 GRAND AVE., SUITE 225, Southlake, TX, 76092
- Phone
- (386) 527-1071
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1667699
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jul 17, 2025 | Amendment | $110,895,239 | $110,895,239 | 59 | May 25, 2023 | sec.gov | |
| Sep 18, 2023 | Amendment | $103,423,054 | $95,905,859 | $7,517,195 | 57 | May 25, 2023 | sec.gov |
| Jun 9, 2023 | New notice | $73,423,067 | $63,805,500 | $9,617,567 | 37 | May 25, 2023 | sec.gov |
| Aug 22, 2022 | Amendment | $25,000,000 | $23,413,102 | $1,586,898 | 18 | Jul 15, 2022 | sec.gov |
| Jul 29, 2022 | New notice | $20,000,000 | $14,926,102 | $5,073,898 | 17 | Jul 15, 2022 | sec.gov |
| Feb 18, 2022 | Amendment | $34,614,335 | $34,614,335 | 30 | Sep 12, 2019 | sec.gov | |
| Jul 15, 2020 | Amendment | $35,000,000 | $19,750,184 | $15,249,816 | 18 | Sep 12, 2019 | sec.gov |
| Nov 19, 2019 | Amendment | $35,000,000 | $16,253,179 | $18,746,821 | 13 | Sep 12, 2019 | sec.gov |
| Sep 23, 2019 | New notice | $3,374,008 | $3,374,008 | 8 | Sep 12, 2019 | sec.gov | |
| May 2, 2016 | Amendment | $12,500,000 | $10,919,000 | $1,581,000 | 112 | Feb 10, 2016 | sec.gov |
| Apr 12, 2016 | Amendment | $12,500,000 | $10,204,000 | $2,296,000 | 101 | Feb 10, 2016 | sec.gov |
| Mar 23, 2016 | Amendment | $12,500,000 | $8,326,500 | $4,173,500 | 81 | Feb 10, 2016 | sec.gov |
| Feb 24, 2016 | New notice | $10,000,000 | $2,897,500 | $7,102,500 | 28 | Feb 10, 2016 | sec.gov |
| Feb 23, 2016 | New notice | $300,000 | $300,000 | 4 | Feb 9, 2016 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jamie Jeffrey Donadio | Executive Officer | |
| Bhupinder Jeffrey Singh | Executive Officer, Director | |
| Carlos Guillem | Director | |
| D. Jeffrey Keyser | Executive Officer, Director | |
| Henrik Jeffrey Rasmussen | Director |
Other pharmaceuticals companies in Texas that filed recently
- LUCIER PHARMACEUTICALS INC offering · Oct 13, 2026
- FibroBiologics, Inc. $1.2 million · Oct 13, 2026
- Eos SENOLYTIX, Inc. $750,000 · Aug 27, 2026
- InnovoTEX Inc. $749,951 · Aug 6, 2026
Every Form D from the week of Jul 14, 2025 · All recent filings in Texas · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Renibus Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.